Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and 2′-O-methyl phosphorothioate offers demonstrated the ability to induce dystrophin manifestation in Duchenne muscular dystrophy (DMD) individuals in stage II-III clinical tests with advantage in muscle tissue functions. dystrophin manifestation in almost 100% skeletal muscle tissue fibers in every age groups. This is from the… Continue reading Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and